Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.

Article Details

Citation

Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F

Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.

Cancer Res. 2006 Nov 15;66(22):10720-8.

PubMed ID
17108108 [ View in PubMed
]
Abstract

The circadian timing system and the cell division cycle are frequently deregulated in cancer. The therapeutic relevance of the reciprocal interactions between both biological rhythms was investigated using Seliciclib, a cyclin-dependent kinase (CDK) inhibitor (CDKI). Mice bearing Glasgow osteosarcoma received Seliciclib (300 mg/kg/d orally) or vehicle for 5 days at Zeitgeber time (ZT) 3, 11, or 19. On day 6, tumor mRNA 24-hour expression patterns were determined for clock genes (Per2, Rev-erbalpha, and Bmal1) and clock-controlled cell cycle genes (c-Myc, Wee1, cyclin B1, and CDK1) with quantitative reverse transcription-PCR. Affinity chromatography on immobilized Seliciclib identified CDK1/CDK2 and extracellular signal-regulated kinase (ERK) 1/ERK2, CDK7/CDK9, and casein kinase CK1epsilon as Seliciclib targets, which respectively regulate cell cycle, transcription, and circadian clock in Glasgow osteosarcoma. Seliciclib reduced tumor growth by 55% following dosing at ZT3 or ZT11 and by 35% at ZT19 compared with controls (P < 0.001). Tolerability was also best at ZT3. Mean transcriptional activity of Rev-erbalpha, Per2, and Bmal1 was arrhythmic in the tumors of untreated mice. Seliciclib induced rhythmic clock gene expression patterns with physiologic phase relations only after ZT3 dosing. c-Myc and Wee1 mRNAs displayed synchronous circadian rhythms in the tumors of control mice receiving vehicle only but not in those of mice given the drug. Seliciclib further enhanced Wee1 expression irrespective of dosing time, an effect that reinforced G(2)-M gating. Seliciclib also inhibited CK1epsilon, which determines circadian period length. The coordination of clock gene expression patterns in tumor cells was associated with best antitumor activity of Seliciclib. The circadian clock and its upstream regulators represent relevant targets for CDKIs.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
SeliciclibCasein kinase I isoform epsilonProteinHumans
Unknown
Not AvailableDetails
SeliciclibCyclin-dependent kinase 1ProteinHumans
Unknown
Not AvailableDetails
SeliciclibCyclin-dependent kinase 2ProteinHumans
Unknown
Not AvailableDetails
SeliciclibCyclin-dependent kinase 7ProteinHumans
Unknown
Not AvailableDetails
SeliciclibCyclin-dependent kinase 9ProteinHumans
Unknown
Not AvailableDetails
SeliciclibMitogen-activated protein kinase 1ProteinHumans
Unknown
Not AvailableDetails
SeliciclibMitogen-activated protein kinase 3ProteinHumans
Unknown
Not AvailableDetails